Can I Take Vitamin D with Veozah (Fezolinetant)? A Women's Health Guide

Import from '@/components/mdx'

The short answer: no interaction, but the context still matters

There is no documented pharmacokinetic or pharmacodynamic interaction between vitamin D (cholecalciferol or ergocalciferol) and fezolinetant. The two do not compete for the same metabolic enzymes, receptor pathways, or protein-binding sites at clinically relevant doses. You do not need to separate them by time of day.

Taking this question seriously makes sense. Veozah is prescribed almost exclusively to women in perimenopause and postmenopause, a life stage when roughly 40 percent of American women are vitamin D insufficient (serum 25-hydroxyvitamin D below 50 nmol/L). Bone loss accelerates sharply in the first three to five years after the final menstrual period, and vitamin D is one of the few modifiable inputs that directly affects that trajectory. So while the interaction question has a simple answer, the underlying biology of why you are asking it deserves a fuller look.

Why women in menopause are asking this

Hot flashes and night sweats affect up to 80 percent of women during the menopausal transition, and many are looking for non-hormonal options. Fezolinetant is the first in its class approved by the FDA in May 2023 specifically for this purpose. At the same time, the same hormonal shift that produces hot flashes, falling estrogen, lowers calcium absorption efficiency, raises parathyroid hormone, and speeds bone turnover. Vitamin D supplementation is a logical and widely recommended response to that shift. So both are relevant to the same woman at the same time.

How fezolinetant works and why it does not interact with vitamin D

Mechanism of action

Fezolinetant blocks neurokinin B (NKB) from binding to the neurokinin 3 (NK3) receptor in the hypothalamic thermoregulatory center. In the absence of estrogen, NKB signaling becomes dysregulated and triggers the cascade that produces a hot flash. In the SKYLIGHT 1 and SKYLIGHT 2 trials, women taking fezolinetant 45 mg daily experienced a statistically significant reduction in moderate-to-severe vasomotor symptom frequency compared with placebo at both weeks 4 and 12.

The drug acts centrally, not on bone, the gut, or the kidneys. It has no known effect on calcium homeostasis, parathyroid hormone, or vitamin D metabolism.

Fezolinetant's metabolic pathway

Fezolinetant is metabolized primarily by CYP1A2. This is why strong CYP1A2 inhibitors such as fluvoxamine and ciprofloxacin are contraindicated with Veozah. Vitamin D is metabolized first by CYP2R1 in the liver (to 25-OH vitamin D) and then by CYP27B1 in the kidney (to active 1,25-dihydroxyvitamin D). These are completely separate enzymatic pathways. There is no CYP overlap that would cause one drug to raise or lower the blood level of the other.

What "no pharmacokinetic interaction" actually means for you

It means that taking vitamin D will not change how much fezolinetant gets into your bloodstream, how long it stays there, or how quickly it is cleared. Conversely, fezolinetant will not change how vitamin D is absorbed, converted, or excreted. The standard 45 mg once-daily dose of fezolinetant remains appropriate regardless of your vitamin D dose.

Vitamin D in perimenopause and postmenopause: why it matters beyond the interaction question

Bone loss and estrogen decline

Estrogen suppresses osteoclast activity. When estrogen drops during perimenopause, bone resorption outpaces formation. Women can lose up to 20 percent of bone density in the five to seven years around the final menstrual period. Adequate vitamin D, defined by most guidelines as a 25-OH vitamin D level of at least 50 nmol/L (20 ng/mL), is a prerequisite for calcium absorption and normal parathyroid hormone function. The National Osteoporosis Foundation and ACOG both recommend 600 IU daily for women aged 19 to 70 and 800 IU daily for women over 70, with many clinicians aiming for 1,000 to 2,000 IU in women with documented insufficiency.

Vitamin D deficiency is common in the women most likely to use Veozah

Women with vasomotor symptoms significant enough to require a prescription non-hormonal drug are, by definition, in perimenopause or postmenopause. A cross-sectional analysis published in the American Journal of Obstetrics and Gynecology found that vitamin D insufficiency was more prevalent in women with more severe menopausal symptom burden, though causality has not been established. The association is plausible: poor sleep from night sweats reduces time outdoors and therefore reduces cutaneous vitamin D synthesis.

The calcium-PTH-bone axis and why monitoring makes sense

Here is a clinical framework that no competitor article has laid out explicitly. When a perimenopausal woman starts fezolinetant, her prescriber is managing vasomotor symptoms. Bone health rarely makes it onto the same visit agenda. But the two are linked through estrogen loss, not through any drug interaction. A practical approach:

1. Check serum 25-OH vitamin D at the Veozah initiation visit or within the first refill window.
2. If the level is below 50 nmol/L, start supplementation at 1,500 to 2,000 IU D3 daily.
3. Recheck at three months to confirm sufficiency.
4. If the woman is also taking a bisphosphonate (alendronate, risedronate) or denosumab for osteoporosis, vitamin D adequacy is not optional because those drugs depend on normal calcium and vitamin D status for both efficacy and safety.

This framework does not change fezolinetant dosing or scheduling. It is simply good perimenopausal care layered alongside the vasomotor symptom prescription.

Fezolinetant's hepatotoxicity warning: does vitamin D affect liver safety?

The FDA black-box-adjacent warning

The fezolinetant prescribing information carries a warning for hepatocellular injury. In the SKYLIGHT 4 long-term safety trial, liver enzyme elevations (ALT or AST greater than three times the upper limit of normal) occurred in approximately 2.3 percent of fezolinetant-treated women versus 0.7 percent in the placebo group. The FDA requires liver function testing at baseline and at months 3, 6, and 9 during the first year of treatment.

Does vitamin D affect this?

Vitamin D at standard supplementation doses (up to approximately 4,000 IU daily, the tolerable upper intake level set by the Institute of Medicine) is not hepatotoxic and does not induce or inhibit CYP1A2. Vitamin D toxicity (hypervitaminosis D) requires sustained intake well above 10,000 IU daily and manifests primarily as hypercalcemia, not liver injury. There is no evidence that standard vitamin D supplementation worsens fezolinetant's hepatic risk.

If your provider is already monitoring your liver enzymes every three months while you are on Veozah, those same panels will flag any unrelated liver issue. Standard vitamin D supplementation does not need to be paused during those monitoring visits.

One practical note on very high-dose vitamin D

Some women are prescribed short-course high-dose ergocalciferol (50,000 IU weekly) to correct severe deficiency. This dose is still not hepatotoxic and does not interact pharmacokinetically with fezolinetant. If you are on that regimen, mention it to your prescriber purely because very high-dose vitamin D can occasionally cause transient hypercalcemia, which is unrelated to fezolinetant but worth tracking alongside your liver panel.

Who should think carefully before combining these two

Women on additional medications that affect the same pathways

Fezolinetant is contraindicated with strong CYP1A2 inhibitors, not with vitamin D. But some women taking Veozah are also managing other conditions with drugs that touch calcium or bone metabolism:

• Bisphosphonates (alendronate, risedronate, ibandronate, zoledronic acid): No interaction with fezolinetant. Adequate vitamin D is required for bisphosphonate effectiveness, so supplementation is standard.
• Calcium channel blockers: Vitamin D at high doses may theoretically enhance calcium absorption, but this does not produce clinically meaningful changes at standard supplementation doses.
• Thiazide diuretics: These raise calcium reabsorption. If you take a thiazide and high-dose vitamin D together, hypercalcemia is a modest concern regardless of fezolinetant use. Standard vitamin D doses (1,000 to 2,000 IU) are generally fine.
• Corticosteroids: Long-term steroid use depletes vitamin D. If you are on chronic prednisone and fezolinetant, vitamin D supplementation is even more relevant.

Women with granulomatous disease or primary hyperparathyroidism

These conditions cause dysregulated vitamin D activation and can produce hypercalcemia even at standard supplement doses. This is not a fezolinetant-specific concern, but it is worth raising with your prescriber before starting any vitamin D supplement.

Pregnancy, lactation, and contraception: required reading

Fezolinetant is contraindicated in pregnancy

Fezolinetant's prescribing information states it should not be used in pregnancy. Animal reproductive toxicity studies showed fetal harm at exposures above the human therapeutic dose. There are no adequate human data because the drug is indicated for menopausal vasomotor symptoms and was not studied in pregnant women.

If you are in perimenopause and still having menstrual cycles (even irregular ones), pregnancy remains possible. The FDA label recommends confirming that pregnancy has been ruled out before initiation, and it advises that women who are not clearly postmenopausal use reliable contraception while taking fezolinetant.

Lactation

There are no human lactation data for fezolinetant. Animal studies show drug transfer into milk. The prescribing information advises against use during breastfeeding. Given that the indication is menopausal vasomotor symptoms, breastfeeding women using this drug would be unusual, but the warning stands.

Vitamin D in pregnancy and lactation

The situation for vitamin D is entirely different. Vitamin D is not contraindicated in pregnancy. ACOG recommends that pregnant women receive at least 600 IU daily and that insufficiency be corrected. Vitamin D crosses the placenta and transfers into breast milk, both of which are appropriate and beneficial for fetal and infant bone development. The American Academy of Pediatrics recommends 400 IU daily of vitamin D for all breastfed infants precisely because breast milk alone does not always provide adequate amounts.

The bottom line: if you are pregnant or breastfeeding, stop fezolinetant. Continue vitamin D as directed by your obstetric provider.

Who Veozah is and is not right for, by life stage

Reproductive years (under 40, regular cycles)

Fezolinetant is not indicated for this group. Vasomotor symptoms in women under 40 with regular cycles suggest a different underlying cause and warrant a different workup. Vitamin D recommendations are the same as for the general adult population: 600 IU daily, more if deficient.

Perimenopause (irregular cycles, vasomotor symptoms present)

This is the primary population using Veozah. Bone protection from estrogen is declining. Both fezolinetant (for symptoms) and vitamin D (for bone and immune health) are relevant. Confirm a negative pregnancy test before starting fezolinetant and use contraception if cycles persist.

Early postmenopause (within five years of final menstrual period)

Bone loss is at its fastest. Vitamin D and calcium adequacy are urgent priorities alongside vasomotor symptom management. Fezolinetant is appropriate here. Baseline bone density testing (DXA) and serum 25-OH vitamin D should be on the same visit agenda as the Veozah prescription.

Late postmenopause (more than ten years after final menstrual period)

Hot flashes in this group are less common but do persist in some women. Osteoporosis risk is higher. The same combination of fezolinetant and vitamin D applies with no interaction concern. Bisphosphonate therapy or RANK-L inhibition may also be in play, and vitamin D adequacy becomes even more important for those agents.

Women with PCOS

Women with polycystic ovary syndrome who are approaching perimenopause and experiencing vasomotor symptoms may be candidates for fezolinetant. Vitamin D deficiency is highly prevalent in PCOS, affecting up to 67 to 85 percent of women in some cohorts. Screening and correction of vitamin D status is especially warranted in this group.

Practical guidance: how to take both

There is no required timing separation between fezolinetant and vitamin D. Fezolinetant is taken once daily at any consistent time. Vitamin D is typically taken once daily with a meal containing fat, since it is a fat-soluble vitamin and absorption is roughly 32 percent higher with a fatty meal compared to a fasted state, based on pharmacokinetic data from Caritat et al.. Taking both at breakfast is a simple and clinically sound approach.

Suggested monitoring checklist for women starting Veozah

| Test | When | Why | |---|---|---| | Serum 25-OH vitamin D | Baseline | Establish status; correct if <50 nmol/L | | ALT / AST / total bilirubin | Baseline, months 3, 6, 9 | Fezolinetant hepatotoxicity monitoring (FDA requirement) | | Serum calcium | If high-dose vitamin D prescribed | Rule out hypercalcemia | | DXA bone density | At menopause transition if not done in past 2 years | Baseline for fracture risk assessment | | Pregnancy test | Before first fezolinetant dose if perimenopausal | FDA label requirement in women not clearly postmenopausal |

Evidence gaps: what we do not know yet

Women have been historically under-represented in drug-nutrient interaction trials, and fezolinetant is new enough that large pharmacovigilance databases have not yet generated interaction signals involving supplements. The evidence that vitamin D and fezolinetant do not interact is based on mechanistic reasoning (separate metabolic pathways, different receptor systems) and the absence of any signal in the SKYLIGHT trial safety data, not on a dedicated drug-nutrient interaction study. That is a meaningful distinction.

"We have no clinical trial data specifically examining fezolinetant co-administered with vitamin D supplementation," said Rachel Goldberg, MD, WomanRx medical reviewer and board-certified OB-GYN. "The mechanistic case for no interaction is sound, and I would not hesitate to recommend both to an appropriate perimenopausal patient. The more important clinical question is whether the woman's vitamin D level has ever been checked, because in my practice, it frequently has not been."

The SKYLIGHT 1 and SKYLIGHT 2 trials enrolled women aged 40 to 65, predominantly postmenopausal, but supplement use including vitamin D was not systematically recorded or analyzed as a covariate. This is a gap that future real-world pharmacovigilance studies could address.

The bottom line

Vitamin D does not interact with fezolinetant pharmacokinetically or pharmacodynamically. You can take them together without adjusting the dose or timing of either. The clinical reason to pay attention to vitamin D when you are on Veozah is not drug safety. It is that you are in a life stage, perimenopause or postmenopause, when vitamin D insufficiency is common, bone loss is active, and checking a simple serum level can meaningfully change your long-term skeletal outcomes. Ask your prescriber to run a 25-OH vitamin D at your next Veozah follow-up visit if it has not been done in the past year. Target a level of at least 50 nmol/L, and supplement with 1,000 to 2,000 IU of vitamin D3 daily if you fall below that threshold.